PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-116.92%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-185.87%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-92.79%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-3998.91%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-3998.91%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
-95.29%
Share count shrinking more than 10% – Aggressive buybacks. Warren Buffett typically welcomes this if undervalued, but watch debt usage for repurchases.
-95.29%
Negative growth in diluted shares typically benefits existing owners. Benjamin Graham would check the sustainability of buybacks or reduction in option overhang.
No Data
No Data available this quarter, please select a different quarter.
75.47%
OCF growth above 20% – Exceptional cash generation improvement. Warren Buffett might see if the net margin also rises in tandem.
66.24%
FCF growth above 20% – Very attractive to value investors. Warren Buffett would check if capital expenditures remain sensible to maintain this level.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.36%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
-420.27%
A negative 5Y OCF/share CAGR indicates declining cash generation per share mid-term. Benjamin Graham would see this as a red flag unless explained by short-term strategic investments.
-362.87%
Negative 3Y OCF/share CAGR shows recent erosion in operating cash. Benjamin Graham would see this as a cautionary signal unless explained by strategic investments.
-427041.90%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-659606.65%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
-1088784.48%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
No Data
No Data available this quarter, please select a different quarter.
-4964.64%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
-1566.95%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Asset growth above 20% – Rapid expansion. Warren Buffett checks if returns justify this investment and if debt finances it unsafely.
57821.37%
Book value/share growth above 12% annually – Strong sign of compounding. Warren Buffett verifies if profits or buybacks mainly drive it.
2.24%
Debt rising up to 5% yoy – Mild increase. Peter Lynch sees expansions or acquisitions possibly justifying modest new debt.
178.96%
R&D growth above 30% – Very high. Philip Fisher demands clear benefits or milestone achievements to justify the spending surge.
203.49%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.